Upstream Bio, Inc.

NASDAQ:UPB

Biotechnology

Healthcare
$2.08 +1.63%

+$0.10 today

Market cap
$114.01M
Beta
1.11
P/E (TTM)
-2.2
EPS (TTM)
-$2.89
52W Low $5.85High $33.68

Volume 1.24M

Average 0.66M

UPB Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Upstream Bio, Inc.NASDAQ: UPB

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $4.65M rose 76.4% year over year, ahead of the +54.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 85.4% from the prior quarter. Over 3 fiscal years it compounded at +100.6% a year.

Context

  • Stock-based compensation amounted to 362.0% of revenue in FY2025, up 108.7 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +76.4% holds above the trailing-twelve-month pace of +54.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.65M+85.4% QoQ
Last fiscal yearDec 2025
$10.33M+72.1% YoY
LTMMar 2026
$12.34M+54.4% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+76.4%——
1 year+72.1%——
3-year CAGR+100.6%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
10.33M USD
Year-over-year change
+72.1%
3-year CAGR
+100.6%

Stock-Based Compensation vs competitors

How UPB compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +54.4% is the 2nd highest of 10, against a peer median of +10.5%.
  • Stock-based compensation amounts to 371.6% of revenue for UPB, versus a peer median of 42.9%.
UPB Competitors
Stock-Based Compensation for UPB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$145.91M USD+2.8%+19.1%220.8%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$50.3M USD+35.9%+74.2%55.6%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$49.18M USD+10.5%+43.7%22.6%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$48.31M USD-34.7%+3.6%466.8%
NVAXNovavax, Inc.LTM Mar 2026$33.45M USD-28.6%-34.9%5.6%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$31.2M USD+11.4%+8.4%—
ZBIOZenas BioPharma, Inc.LTM Mar 2026$30.16M USD+97.6%+229.4%—
WVEWave Life Sciences Ltd.LTM Mar 2026$21.73M USD+42.8%—30.3%
PHVSPharvaris N.V.LTM Sep 2026€17.97M EUR-7.1%+18.8%—
UPBUpstream Bio, Inc.LTM Mar 2026$12.34M USD+54.4%+100.6%371.6%
Peer median (excluding UPB) —+10.5%+19.0%42.9%

Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(23.87M)(20.54M)(62.81M)(143.44M)
Depreciation & Amortization7K60K89K(1.31M)
Deferred Income Tax0000
Stock-Based Compensation1.28M3.43M6M10.33M
Change in Working Capital3.41M(4.31M)1.87M589K
Accounts Receivables(412K)314K(515K)(55K)
Inventory0000
Accounts Payables462K1.28M2.02M(1.28M)
Other Working Capital3.36M(5.9M)371K1.93M
Other Non-Cash Items149K(16.57M)(4.33M)561K
Operating Cash Flow(19.02M)(37.93M)(59.17M)(133.28M)
Capital Expenditures(82K)(144K)(511K)(165K)
Acquisitions (Net)0000
Purchases of Investments0(128.99M)(290.61M)(385.88M)
Sales of Investments046.29M231.64M292.56M
Other Investing Activities0000
Investing Cash Flow(82K)(82.84M)(59.49M)(93.48M)
Debt Repayment0000
Common Stock Issued9.96M129.55M272.72M2.44M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities(37K)118K(3.74M)0
Financing Cash Flow9.96M129.55M418.91M2.44M
Effect of Forex Changes0000
Net Change in Cash(9.14M)8.78M300.25M(224.31M)
Free Cash Flow(19.1M)(38.07M)(59.68M)(133.28M)

Upstream Bio, Inc.

NASDAQ:UPB

Intrinsic Alpha fair value

Locked

Current Price

$2.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.